Evidence-based urology in practice: composite endpoints

BJU Int. 2010 Sep;106(5):610-2. doi: 10.1111/j.1464-410X.2010.09455.x. Epub 2010 Jun 14.

Authors

Luke T Lavallée¹, Philipp Dahm, Rodney H Breau

Affiliation

¹ Division of Urology, University of Ottawa, Ottawa, ON, Canada.

PMID: 20553252
DOI: 10.1111/j.1464-410X.2010.09455.x

No abstract available

MeSH terms

5-alpha Reductase Inhibitors / therapeutic use*
Doxazosin / therapeutic use*
Drug Therapy, Combination
Endpoint Determination
Evidence-Based Medicine*
Finasteride / therapeutic use*
Humans
Male
Middle Aged
Prostatic Hyperplasia / complications
Prostatic Hyperplasia / drug therapy*
Prostatism / drug therapy*
Prostatism / etiology
Risk Reduction Behavior
Treatment Outcome

Substances

5-alpha Reductase Inhibitors
Finasteride
Doxazosin